Immediate Impact
65 standout
Citing Papers
HER2-targeted therapies in cancer: a systematic review
2024 Standout
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
2024 Standout
Works of Vanessa Petry being referenced
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
2021
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Vanessa Petry | 224 | 66 | 86 | 71 | 23 | 354 | |
| C. Griso | 78 | 38 | 117 | 21 | 18 | 328 | |
| Todd V. Cartee | 176 | 84 | 63 | 52 | 32 | 357 | |
| L. Vilardell | 120 | 25 | 98 | 86 | 20 | 338 | |
| M. Dorreen | 150 | 28 | 79 | 18 | 23 | 388 | |
| Andrew Watters | 92 | 122 | 108 | 81 | 20 | 391 | |
| Mitsuo Terada | 229 | 26 | 76 | 15 | 35 | 383 | |
| LiVolsi Va | 145 | 13 | 39 | 66 | 19 | 406 | |
| Maria Carolina Gelli | 78 | 25 | 44 | 74 | 32 | 353 | |
| Patricia Kellett | 195 | 85 | 32 | 99 | 18 | 319 | |
| Ola El‐Zammar | 107 | 17 | 142 | 146 | 22 | 372 |
All Works
Login with ORCID to disown or claim papers
Loading papers...